📊 DTIL Key Takeaways
Is Precision Biosciences Inc. (DTIL) a Good Investment?
Precision Biosciences exhibits severe operational deterioration with 50% YoY revenue decline, operating losses of -83.7% margin, and negative free cash flow of -12.0M, indicating a pre-commercial biotech burning significant capital. While the company maintains a strong cash position of 99.4M providing ~8 years of runway, the lack of revenue traction and accelerating losses on a shrinking revenue base suggest failed product development or partnership challenges. Current fundamentals indicate a struggling asset in distress absent meaningful clinical or commercial inflection.
Precision BioSciences shows weak core fundamentals, with revenue down 50.1% year over year, deeply negative operating and net margins, and substantial free cash flow burn. The balance sheet is currently supported by a large cash position, strong liquidity, and modest leverage, but the company’s cash runway is limited if operating losses and cash outflows persist. Growth quality appears low at this stage because declining revenue is being paired with heavy losses rather than improving operating efficiency.
Why Buy Precision Biosciences Inc. Stock? DTIL Key Strengths
- Strong liquidity position with 99.4M cash and 14.02x current ratio
- Conservative leverage with 0.29x debt/equity ratio
- Manageable debt burden of 22.3M relative to equity base of 76.1M
- Strong liquidity with $110.82M in cash and current ratio of 13.32x
- Low balance sheet leverage with debt-to-equity of 0.24x
- Positive equity base of $92.25M provides some financial flexibility
DTIL Stock Risks: Precision Biosciences Inc. Investment Risks
- Revenue collapse of 50.1% YoY indicates loss of product commercialization or failed partnerships
- Negative free cash flow of -12.0M with deteriorating operating performance suggests escalating burn rate
- Operating margin of -83.7% and net margin of -170.2% show unsustainable unit economics and severe losses
- Declining EPS (-442.3% YoY) with negative ROE (-24.2%) destroys shareholder value
- Revenue declined 50.1% year over year, indicating weak top-line momentum
- Operating margin of -152.2% and net margin of -133.4% reflect an unsustainable profitability profile
- Operating cash outflow of $65.84M versus $110.82M cash suggests meaningful funding risk if burn continues
Key Metrics to Watch
- Quarterly revenue trend - stabilization or continued contraction signals viability
- Operating cash burn rate relative to cash runway
- Clinical trial progress or partnership announcements that could restore revenue growth
- Quarterly cash burn relative to cash and equivalents
- Revenue stability and progress toward narrower operating losses
Precision Biosciences Inc. (DTIL) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 14.02x current ratio provides a solid financial cushion.
DTIL Profit Margin, ROE & Profitability Analysis
DTIL vs Healthcare Sector: How Precision Biosciences Inc. Compares
How Precision Biosciences Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Precision Biosciences Inc. Stock Overvalued? DTIL Valuation Analysis 2026
Based on fundamental analysis, Precision Biosciences Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Precision Biosciences Inc. Balance Sheet: DTIL Debt, Cash & Liquidity
DTIL Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Precision Biosciences Inc.'s revenue has declined by 41% over the 5-year period, indicating business contraction. The most recent EPS of $1.04 reflects profitable operations.
DTIL Revenue Growth, EPS Growth & YoY Performance
DTIL Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $29.0K | -$18.4M | $-0.75 |
| Q3 2025 | $13.0K | $8.6M | $-1.84 |
| Q2 2025 | $18.0K | $8.6M | $-2.13 |
| Q1 2025 | $29.0K | $8.6M | $1.70 |
| Q3 2024 | $576.0K | -$8.1M | $-2.10 |
| Q2 2024 | $19.8M | $8.6M | $-3.13 |
| Q1 2024 | $8.8M | $8.6M | $1.70 |
| Q3 2023 | $7.4M | -$8.1M | $-0.07 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Precision Biosciences Inc. Dividends, Buybacks & Capital Allocation
DTIL SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Precision Biosciences Inc. (CIK: 0001357874)
📋 Recent SEC Filings
❓ Frequently Asked Questions about DTIL
What is the AI rating for DTIL?
Precision Biosciences Inc. (DTIL) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 82% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are DTIL's key strengths?
Claude: Strong liquidity position with 99.4M cash and 14.02x current ratio. Conservative leverage with 0.29x debt/equity ratio. ChatGPT: Strong liquidity with $110.82M in cash and current ratio of 13.32x. Low balance sheet leverage with debt-to-equity of 0.24x.
What are the risks of investing in DTIL?
Claude: Revenue collapse of 50.1% YoY indicates loss of product commercialization or failed partnerships. Negative free cash flow of -12.0M with deteriorating operating performance suggests escalating burn rate. ChatGPT: Revenue declined 50.1% year over year, indicating weak top-line momentum. Operating margin of -152.2% and net margin of -133.4% reflect an unsustainable profitability profile.
What is DTIL's revenue and growth?
Precision Biosciences Inc. reported revenue of $10.8M.
Does DTIL pay dividends?
Precision Biosciences Inc. does not currently pay dividends.
Where can I find DTIL SEC filings?
Official SEC filings for Precision Biosciences Inc. (CIK: 0001357874) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is DTIL's EPS?
Precision Biosciences Inc. has a diluted EPS of $-0.75.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is DTIL a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Precision Biosciences Inc. has a SELL rating with 82% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is DTIL stock overvalued or undervalued?
Valuation metrics for DTIL: ROE of -24.2% (sector avg: 15%), net margin of -170.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy DTIL stock in 2026?
Our dual AI analysis gives Precision Biosciences Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is DTIL's free cash flow?
Precision Biosciences Inc.'s operating cash flow is $-11.9M, with capital expenditures of $18.0K. FCF margin is -110.3%.
How does DTIL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -170.2% (avg: 12%), ROE -24.2% (avg: 15%), current ratio 14.02 (avg: 2).